ALL PODCASTS

  • 3 October 2022 Speaker: Dr Jimmy Teo Boon Wee, Dr Tan Li Ping SC-SG-01270 What is new in SGLT2 inhibitor and CKD?
    Our host speaks with Assoc Prof Jimmy Teo, Senior Consultant nephrologist from National University Hospital Singapore and Dr Tan Li Ping, Consultant Nephrologist from Ara Damansara Medical Centre Malaysia, to discuss the baseline characteristics of EMPA-Kidney trial, the latest study in SGLT2 inhibitor and CKD.
    Note: Empagliflozin is not indicated for the treatment of chronic kidney disease.

    Reference:

    1. EMPA-KIDNEY Collaborative Group. Nephrol Dial Transplant. 2022 Jun 23;37(7):1317-1329.